To study the therapeutic effect of bevacizumab combined with paclitaxel and platinum chemotherapy for patients with on advanced cervical cancer. Methods: 120 patients with advanced cervical cancer were selected and were divided into observation group (60 cases) and control group (60 cases) from April 2021 to August 2023. After receiving radiotherapy, the patients in the two groups received chemotherapy with paclitaxel combined with platinum drugs, while the patients in the observation group received treatment of paclitaxel combined with platinum drugs and bevacizumab. The pain and survival status, the clinical efficacy, the T lymphocyte subsets and the tumor markers levels, and the adverse reactions situation of the patients in the two groups were observed. Results: The pain scores by VAS (2.03±0.24 points and 3.16±0.33 points), the serum carbohydrate antigen 125 (CA125) level (22.24±2.30 U/ml and 31.46±3.04 U/ml), the carcinoembryonic antigen (CEA) level (2.11±0.22μg/L and 3.67±0.30μg/L), the squamous cell carcinoma antigen (SCCA) level (4.01±0.39μg/L and 6.21±0.51μg/L) and the CD8+ level of the patients in the two groups after treatment were significantly lower than those before treatment. The KPS quality of life score (85.20±8.45 points and 73.43±7.31 points), the CD3+ and CD4+ levels, and the effective rate (66.7% and 40.0%) of the patients in the two groups after treatment were significantly higher than those before treatment, and the changes of the patients in the observation group were significantly more than those of the patients in the control group (all P<0.05). There was no significant difference in the adverse reactions rate (26.7% vs 20.0%) of the patients between the two groups (P>0.05). After treatment, the VAS score, and the serum CA125, CEA, SCCA, and CD8+levels of the patients in both groups were significantly reduced (P<0.05), and the reduction effect in the observation group was significantly better than that in the control group (P<0.05). The KPS score, the CD3+ and CD4+levels, and the effective rate of the patients in the two groups had increased significantly (P<0.05), and which of the patients in the observation group were significantly better than the control group (P<0.05). There was no significant difference in the adverse reactions rate of the patients between the two groups (P>0.05). Conclusion: The combination chemotherapy of bevacizumab, paclitaxel and platinum for treating the patients with advanced cervical cancer has good therapeutic effect, and without increase of the adverse reactions.